• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Keratoacanthoma Companies

    ID: MRFR/MED/1233-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Keratoacanthoma is a type of skin tumor that often resembles squamous cell carcinoma but typically grows rapidly and may resolve spontaneously. It is generally considered a low-grade, non-invasive form of skin cancer. Medical professionals, including dermatologists and oncologists, are involved in the diagnosis and treatment of keratoacanthoma.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Keratoacanthoma Market Research Report-Forecast to 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Keratoacanthoma Market

    Keratoacanthoma Key Companies

     

    Latest Keratoacanthoma Companies Update


    Almirall, S.A. Presented positive Phase 2a data for Klisyri (ciclopirox olamine) ointment in July 2023, demonstrating its efficacy and safety for the treatment of facial keratoacanthoma. This data provides promising insights for further development of this potential therapy.


    Medicure Pharma Initiated a Phase 2 clinical trial in October 2023 to evaluate the effectiveness of a topical formulation of MC0427 for the treatment of keratoacanthoma. This trial could pave the way for a novel treatment option with potentially fewer side effects than existing therapies.


    List of Keratoacanthoma Key Companies in the Market



    • Cipla Ltd.

    • GE Healthcare

    • Glenmark Pharmaceuticals Ltd.

    • Hospira

    • Pfizer

    • Philips Healthcare

    • Ranbaxy Laboratories Ltd.

    • Bausch Health Companies Inc.

    • Sanofi

    • Siemens Healthcare